Armata Pharmaceuticals, Inc. (ARMP) - Form 8-K Summary
Business Context and Reporting Period
Armata Pharmaceuticals, Inc. filed this Form 8-K on August 12, 2026, to announce financial results for the three and six months ended June 30, 2026. The company is incorporated in Washington and trades on the NYSE American under the symbol ARMP.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
No material changes versus the prior comparable period are described in the filing text. The document serves solely as a notification that results have been announced.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 12, 2026) for specific financial figures.
- Verify the company's cash runway and burn rate given the lack of revenue disclosure in this summary.
- Confirm the status of clinical trials or product development milestones referenced in the full press release.
- Check for any forward-looking statements or updated guidance in the full exhibit.